nach oben

Erschienen in:

01.01.2015 | REVIEW

Determinants of the prevalence of gout in the general population: a systematic review and meta-regression

verfasst von: José M. A. Wijnands, Wolfgang Viechtbauer, Kristof Thevissen, Ilja C. W. Arts, Pieter C. Dagnelie, Coen D. A. Stehouwer, Sjef van der Linden, Annelies Boonen

Erschienen in: European Journal of Epidemiology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Studies on the occurrence of gout show a large range in estimates. However, a clear insight into the factors responsible for this variation in estimates is lacking. Therefore, our aim was to review the literature on the prevalence and incidence of gout systematically and to obtain insight into the degree of and factors contributing to the heterogeneity. We searched MEDLINE, EMBASE, and Web of Science (January 1962 to July 2012) to identify primary studies on the prevalence and incidence of gout in the general population. Data were extracted by two persons on sources of clinical heterogeneity, methodological heterogeneity, and variation in outcome reporting. Meta-analysis and meta-regression analysis were performed for the prevalence of gout. Of 1,466 articles screened, 77 articles were included, of which 71 reported the prevalence and 12 the incidence of gout. The pooled prevalence (67 studies; N = 12,226,425) based on a random effects model was 0.6 % (95 % CI 0.4; 0.7), however there was a high level of heterogeneity (I² = 99.9 %). Results from a mixed-effects meta-regression model indicated that age (p = 0.019), sex (p < 0.001), continent (p < 0.001), response rate (p = 0.016), consistency in data collection (p = 0.002), and case definition (p < 0.001) were significantly associated with gout prevalence and jointly accounted for 88.7 % of the heterogeneity. The incidence in the total population ranged from 0.06 to 2.68 per 1,000 person-years. In conclusion, gout is a common disease and the large variation in the prevalence data on gout is explained by sex, continent on which the study was performed, and the case definition of gout.

Nur mit Berechtigung zugänglich

Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med. 2012;125:679–87. doi:10.1016/j.amjmed.2011.09.033.PubMed

Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case-control study. Rheumatology. 2007;46:1441–4.PubMed

Hamburger M, Baraf HS, Adamson TC 3rd, Basile J, Bass L, Cole B, et al. 2011 Recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med. 2011;123:3–36. doi:10.3810/pgm.2011.11.2511.PubMed

Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther. 2006;8:S2.PubMedCentralPubMed

Singh JA. Racial and gender disparities among patients with gout. Curr Rheumatol Rep. 2013;15:307. doi:10.1007/s11926-012-0307-x.PubMedCentralPubMed

Doherty M. New insights into the epidemiology of gout. Rheumatology. 2009;48:2–8.

Luk AJ, Simkin PA. Epidemiology of hyperuricemia and gout. Am J Manag Care. 2005;11:S435–42.PubMed

Miller DR, Rogers WH, Kazis LE, Spiro A 3rd, Ren XS, Haffer SC. Patients’ self-report of diseases in the Medicare Health Outcomes Survey based on comparisons with linked survey and medical data from the Veterans Health Administration. J Ambul Care Manage. 2008;31:161–77. doi:10.1097/01.JAC.0000314707.88160.9c.PubMed

Malik A, Dinnella JE, Kwoh CK, Schumacher HR. Poor validation of medical record ICD-9 diagnoses of gout in a Veterans Affairs Database. J Rheumatol. 2009;36:1283–6.PubMed

10.

Cheng LSC, Chiang SL, Tu HP, Chang SJ, Wang TN, Ko AMJ, et al. Genomewide scan for gout in Taiwanese aborigines reveals linkage to chromosome 4q25. Am J Hum Genet. 2004;75:498–503.PubMed

11.

Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for meta-analysis in medical research. New York: Wiley; 2000.

12.

Lipsey MW, Wilson DB. Practical meta-analysis. Thousand Oaks, CA: Sage; 2001.

13.

Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ. 2011;342:d549. doi:10.1136/bmj.d549.PubMed

14.

Berkey CS, Hoaglin DC, Mosteller F, Colditz GA. A random-effects regression model for meta-analysis. Stat Med. 1995;14:395–411.PubMed

15.

Greenland S, O’Rourke K. On the bias produced by quality scores in meta-analysis, and a hierarchical view of proposed solutions. Biostatistics. 2001;2:463–71. doi:10.1093/biostatistics/2.4.463.PubMed

16.

Raudenbush SW. Analyzing effect sizes: random-effects models. In: Cooper H, Hedges LV, Valentine JC, editors. The handbook of research synthesis and meta-analysis. 2nd ed. New York: Russell Sage Foundation; 2009. p. 295–315.

17.

Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. Stat Med. 2003;22:2693–710. doi:10.1002/sim.1482.PubMed

18.

Holm S. A simple sequentially rejective multiple test procedure. Scand J Statist. 1979;6:65–70.

19.

Viechtbauer W. Conducting meta-analyses in R with the metafor Package. J Stat Softw. 2010;36:1–48.

20.

Bates D, Maechler M, Bolker B, Walker S. lme4: Linear mixed-effects models using Eigen and S4. R package version 1.1–6 2014. http://CRAN.R-project.org/package=lme4.

21.

Yee TW. The VGAM package for categorical data analysis. J Stat Softw. 2010;32:1–34.

22.

Akizuki S. A population study of hyperuricaemia and gout in Japan–analysis of sex, age and occupational differences in thirty-four thousand people living in Nagano Prefecture. Ryumachi. 1982;22:201–8.PubMed

23.

Al-Arfaj AS. Hyperuricemia in Saudi Arabia. Rheumatol Int. 2001;20:61–4.PubMed

24.

Alvarez Nemegyei J, Nuno Gutierrez BL, Alcocer Sanchez JA. Enfermedades reumaticas y discapacidad laboral en poblacion adulta rural. Rev Med Inst Mex Seguro Soc. 2005;43:287–92.PubMed

25.

Anagnostopoulos I, Zinzaras E, Alexiou I, Papathanasiou AA, Davas E, Koutroumpas A, et al. The prevalence of rheumatic diseases in central Greece: a population survey. BMC Musculoskelet Disord. 2010;11:98. doi:10.1186/1471-2474-11-98.PubMedCentralPubMed

26.

Andrianakos A, Trontzas P, Christoyannis F, Dantis P, Voudouris C, Georgountzos A, et al. Prevalence of rheumatic diseases in Greece: a cross-sectional population based epidemiological study. The ESORDIG Study. J Rheumatol. 2003;30:1589–601.PubMed

27.

Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis. 2008;67:960–6.PubMedCentralPubMed

28.

Badley EM, Meyrick JS, Wood PH. Gout and serum uric acid levels in the Cotswolds. Rheumatol Rehabil. 1978;17:133–42.PubMed

29.

Beighton P, Solomon L, Soskolne CL, Sweet MB. Rheumatic disorders in the South African Negro. Part IV. Gout and hyperuricaemia. S Afr Med J. 1977;51:969–72.PubMed

30.

Beighton P, Valkenburg HA. Bone and joint disorders on Tristan da Cunha. S Afr Med J. 1974;48:743–7.PubMed

31.

Bergmann MM, Jacobs EJ, Hoffmann K, Boeing H. Agreement of self-reported medical history: comparison of an in-person interview with a self-administered questionnaire. Eur J Epidemiol. 2004;19:411–6.PubMed

32.

Bergstrom G, Bjelle A, Sorensen LB, Sundh V, Svanborg A. Prevalence of rheumatoid arthritis, osteoarthritis, chondrocalcinosis and gouty arthritis at age 79. J Rheumatol. 1986;13:527–34.PubMed

33.

Boyer GS, Lanier AP, Templin DW. Prevalence rates of spondyloarthropathies, rheumatoid arthritis, and other rheumatic disorders in an Alaskan Inupiat Eskimo population. J Rheumatol. 1988;15:678–83.PubMed

34.

Brauer GW, Prior IA. A prospective study of gout in New Zealand Maoris. Ann Rheum Dis. 1978;37:466–72.PubMedCentralPubMed

35.

Cakir N, Pamuk ON, Dervis E, Imeryuz N, Uslu H, Benian O, et al. The prevalences of some rheumatic diseases in western Turkey: Havsa study. Rheumatol Int. 2012;32:895–908. doi:10.1007/s00296-010-1699-4.PubMed

36.

Cardiel MH, Rojas-Serrano J. Community based study to estimate prevalence, burden of illness and help seeking behavior in rheumatic diseases in Mexico City. A COPCORD study. Clin Exp Rheumatol. 2002;20:617–24.PubMed

37.

Chaiamnuay P, Darmawan J, Muirden KD, Assawatanabodee P. Epidemiology of rheumatic disease in rural Thailand: a WHO-ILAR COPCORD study. Community Oriented Programme for the Control of Rheumatic Disease. J Rheumatol. 1998;25:1382–7.PubMed

38.

Chang SJ, Ko YC, Wang TN, Chang FT, Cinkotai FF, Chen CJ. High prevalence of gout and related risk factors in Taiwan’s Aborigines. J Rheumatol. 1997;24:1364–9.PubMed

39.

Chen SL, Du H, Wang Y, Xu LQ. The epidemiology study of hyperuricemia and gout in a community population of Huangpu District in Shanghai. Chin Med J. 1998;111:228–30.PubMed

40.

Chopra A, Patil J, Billempelly V, Relwani J, Tandle HS. Prevalence of rheumatic diseases in a rural population in western India: a WHO-ILAR COPCORD Study. J Assoc Physicians India. 2001;49:240–6.PubMed

41.

Chou CT, Lai JS. The epidemiology of hyperuricaemia and gout in Taiwan aborigines. Br J Rheumatol. 1998;37:258–62.PubMed

42.

Chou CT, Pei L, Chang DM, Lee CF, Schumacher HR, Liang MH. Prevalence of rheumatic diseases in Taiwan: a population study of urban, suburban, rural differences. J Rheumatol. 1994;21:302–6.PubMed

43.

Chuang SY, Lee SC, Hsieh YT, Pan WH. Trends in hyperuricemia and gout prevalence: nutrition and health survey in Taiwan from 1993–1996 to 2005–2008. Asia Pac J Clin Nutr. 2011;20:301–8.PubMed

44.

Currie WJ. Prevalence and incidence of the diagnosis of gout in Great Britain. Ann Rheum Dis. 1979;38:101–6.PubMedCentralPubMed

45.

Dai SM, Han XH, Zhao DB, Shi YQ, Liu Y, Meng JM. Prevalence of rheumatic symptoms, rheumatoid arthritis, ankylosing spondylitis, and gout in Shanghai, China: a COPCORD study. J Rheumatol. 2003;30:2245–51.PubMed

46.

Dans LF, TankehTorres S, Amante CM, Penserga EG. The prevalence of rheumatic diseases in a Filipino urban population: a WHO-ILAR COPCORD study. J Rheumatol. 1997;24:1814–9.PubMed

47.

Darmawan J, Valkenburg HA, Muirden KD, Wigley RD. The epidemiology of gout and hyperuricemia in a rural population of Java. J Rheumatol. 1992;19:1595–9.PubMed

48.

Davatchi F, Jamshidi AR, Banihashemi AT, Gholami J, Forouzanfar MH, Akhlaghi M, et al. Effect of ethnic origin (Caucasians versus Turks) on the prevalence of rheumatic diseases: a WHO-ILAR COPCORD urban study in Iran. Clin Rheumatol. 2009;28:1275–82.PubMed

49.

Douglas WA. Rheumatic disease in the Australian Aborigine of Cape York Peninsula: a 1965 study. APLAR J Rheumatol. 2004;7:237–41. doi:10.1111/j.1479-8077.2004.00098.x.

50.

Elliot AJ, Cross KW, Fleming DM. Seasonality and trends in the incidence and prevalence of gout in England and Wales 1994–2007. Ann Rheum Dis. 2009;68:1728–33.PubMed

51.

Farooqi A, Gibson T. Prevalence of the major rheumatic disorders in the adult population of north Pakistan. Br J Rheumatol. 1998;37:491–5.PubMed

52.

Gardner MJ, Power C, Barker DJ, Padday R. The prevalence of gout in three English towns. Int J Epidemiol. 1982;11:71–5.PubMed

53.

Hall AP, Barry PE, Dawber TR, McNamara PM. Epidemiology of gout and hyperuricemia. A long-term population study. Am J Med. 1967;42:27–37.PubMed

54.

Hanova P, Pavelka K, Dostal C, Holcatova I, Pikhart H. Epidemiology of rheumatoid arthritis, juvenile idiopathic arthritis and gout in two regions of the Czech Republic in a descriptive population-based survey in 2002–2003. Clin Exp Rheumatol. 2006;24:499–507.PubMed

55.

Haq SA, Darmawan J, Islam MN, Uddin MZ, Das BB, Rahman F, et al. Prevalence of rheumatic diseases and associated outcomes in rural and urban communities in Bangladesh: a COPCORD study. J Rheumatol. 2005;32:348–53.PubMed

56.

Harris CM, Lloyd D, Lewis J. Prevalence and Prophylaxis of Gout in England. J Clin Epidemiol. 1995;48:1153–8.PubMed

57.

Hoa TTM, Damarwan J, Le CS, Hung NV, Nhi CT, An TN. Prevalence of the rheumatic diseases in urban Vietnam: a WHO-ILAR COPCORD study. J Rheumatol. 2003;30:2252–6.

58.

Jackson L, Taylor R, Faaiuso S, Ainuu SP, Whitehouse S, Zimmet P. Hyperuricaemia and gout in Western Samoans. J Chronic Dis. 1981;34:65–75.PubMed

59.

Joshi VL, Chopra A. Is there an urban-rural divide? Population surveys of rheumatic musculoskeletal disorders in the Pune region of India using the COPCORD Bhigwan Model. J Rheumatol. 2009;36:614–22.PubMed

60.

Kato H, Duff IF, Russell WJ, Uda Y, Hamilton HB, Kawamoto S, et al. Rheumatoid arthritis and gout in Hiroshima and Nagasaki, Japan: a prevalence and incidence study. J Chronic Dis. 1971;23:659–79.PubMed

61.

Klemp P, Stansfield SA, Castle B, Robertson MC. Gout is on the increase in New Zealand. Ann Rheum Dis. 1997;56:22–6.PubMedCentralPubMed

62.

Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988–1994. Am J Kidney Dis. 2002;40:37–42.PubMed

63.

Li R, Sun J, Ren LM, Wang HY, Liu WH, Zhang XW, et al. Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing. Rheumatology. 2012;51:721–9. doi:10.1093/rheumatology/ker370.PubMed

64.

Mahajan A, Jasrotia DS, Manhas AS, Jamwal SS. Prevalence of major rheumatic disorders in Jammu. JK Sci. 2003;5:63–6.

65.

Miao ZM, Li CG, Chen Y, Zhao SH, Wang YG, Wang ZC, et al. Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. J Rheumatol. 2008;35:1859–64.PubMed

66.

Mikkelsen WM, Dodge HJ, Duff IF, Kato H. Estimates of the prevalence of rheumatic diseases in the population of Tecumseh, Michigan, 1959–60. J Chronic Dis. 1967;20:351–69.PubMed

67.

Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR, Saag KG. Gout epidemiology: results from the UK general practice research database, 1990–1999. Ann Rheum Dis. 2005;64:267–72.PubMedCentralPubMed

68.

Minaur N, Sawyers S, Parker J, Darmawan J. Rheumatic disease in an Australian aboriginal community in North Queensland, Australia. A WHO-ILAR COPCORD survey. J Rheumatol. 2004;31:965–72.PubMed

69.

Nan HR, Qiao Q, Dong YH, Gao WG, Tang B, Qian RL, et al. The prevalence of hyperuricemia in a population of the coastal city of Qingdao, China. J Rheumatol. 2006;33:1346–50.PubMed

70.

Obregon-Ponce A, Iraheta I, Garcia-Ferrer H, Mejia B, Garcia-Kutzbach A. Prevalence of musculoskeletal diseases in Guatemala, Central America: the COPCORD study of 2 populations. J Clin Rheumatol. 2012;18:170–4. doi:10.1097/RHU.0b013e3182583803.PubMed

71.

O’Sullivan JB. Gout in a New England town. A prevalence study in Sudbury, Massachusetts. Ann Rheum Dis. 1972;31:166–9.PubMedCentralPubMed

72.

Pelaez-Ballestas I, Sanin LH, Moreno-Montoya J, Alvarez-Nemegyei J, Burgos-Vargas R, Garza-Elizondo M, et al. Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology. J Rheumatol. 2011;86:3–8. doi:10.3899/jrheum.100951.

73.

Picavet HS, Hazes JM. Prevalence of self reported musculoskeletal diseases is high. Ann Rheum Dis. 2003;62:644–50.PubMedCentralPubMed

74.

Popert AJ, Hewitt JV. Gout and hyperuricaemia in rural and urban populations. Ann Rheum Dis. 1962;21:154–63.PubMedCentralPubMed

75.

Portis AJ, Laliberte M, Tatman P, Moua M, Culhane-Pera K, Maalouf NM, et al. High prevalence of gouty arthritis among the Hmong population in Minnesota. Arthritis Care Res (Hoboken). 2010;62:1386–91. doi:10.1002/acr.20232.

76.

Prior IA, Rose BS, Harvey HP, Davidson F. Hyperuricaemia, gout, and diabetic abnormality in Polynesian people. Lancet. 1966;1:333–8.PubMed

77.

Reyes-Llerena GA, Guibert-Toledano M, Penedo-Coello A, Perez-Rodriguez A, Baez-Duenas RM, Charnicharo-Vidal R, et al. Community-based study to estimate prevalence and burden of illness of rheumatic diseases in Cuba: a COPCORD study. J Clin Rheumatol. 2009;15:51–5.PubMed

78.

Rose BS, Prior IA. A survey of rheumatism in a rural New Zealand Maori community. Ann Rheum Dis. 1963;22:410–5.PubMedCentralPubMed

79.

Salaffi F, De Angelis R, Grassi W. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol. 2005;23:819–28.PubMed

80.

Sari I, Akar S, Pakoz B, Sisman AR, Gurler O, Birlik M, et al. Hyperuricemia and its related factors in an urban population, Izmir, Turkey. Rheumatol Int. 2009;29:869–74.PubMed

81.

Steven MM. Prevalence of chronic arthritis in four geographical areas of the Scottish Highlands. Ann Rheum Dis. 1992;51:186–94.PubMedCentralPubMed

82.

Sullivan FM, Barber JH, Sturrock RD. Rheumatology at the general practitioner/hospital interface: a study of prevalence and access to specialist care. Ann Rheum Dis. 1990;49:983–5.PubMedCentralPubMed

83.

Taylor W, Smeets L, Hall J, McPherson K. The burden of rheumatic disorders in general practice: consultation rates for rheumatic disease and the relationship to age, ethnicity, and small-area deprivation. N Z Med J. 2004;117:U1098.PubMed

84.

Trifiro G, Morabito P, Cavagna L, Ferrajolo C, Pecchioli S, Simonetti M, et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005–2009: a nationwide population-based study. Ann Rheum Dis. 2012;72:694–700. doi:10.1136/annrheumdis-2011-201254.PubMed

85.

Veerapen K, Wigley RD, Valkenburg H. Musculoskeletal pain in Malaysia: a COPCORD survey. J Rheumatol. 2007;34:207–13.PubMed

86.

Wigley R, Manahan L, Muirden KD, Caragay R, Pinfold B, Couchman KG, et al. Rheumatic disease in a Philippine village II: a WHO-ILAR-APLAR COPCORD study, phases II and III. Rheumatol Int. 1991;11:157–61.PubMed

87.

Winnard D, Wright C, Taylor WJ, Jackson G, Te Karu L, Gow PJ, et al. National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology. 2012;51:901–9. doi:10.1093/rheumatology/ker361.PubMed

88.

Zalokar J, Lellouch J, Claude JR, Kuntz D. Serum uric acid in 23,923 men and gout in a subsample of 4257 men in France. J Chronic Dis. 1972;25:305–12.PubMed

89.

Zeng QY, Wang QW, Chen R, Xiao ZG, Huang SB, Xu JC. Primary gout in Shantou: a clinical and epidemiological study. Chin Med J. 2003;116:66–9.PubMed

90.

Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63:3136–41. doi:10.1002/art.30520.PubMed

91.

Zimmet PZ, Whitehouse S, Jackson L, Thoma K. High prevalence of hyperuricaemia and gout in an urbanised Micronesian population. Br Med J. 1978;1:1237–9.PubMedCentralPubMed

92.

Lin KC, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. J Rheumatol. 2000;27:1045–50.PubMed

93.

Arromdee E, Michet CJ, Crowson CS, O’Fallon WM, Gabriel SE. Epidemiology of gout: Is the incidence rising? J Rheumatol. 2002;29:2403–6.PubMed

94.

Bhole V, de Vera M, Rahman MM, Krishnan E, Choi H. Epidemiology of female gout: 52-Year follow-up of a prospective cohort. Arthritis Rheum. 2010;62:1069–76.PubMed

95.

Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987;82:421–6.PubMed

96.

Isomaki H, Raunio J, von Essen R, Hameenkorpi R. Incidence of inflammatory rheumatic diseases in Finland. Scand J Rheumatol. 1978;7:188–92.PubMed

97.

O’Sullivan JB. The incidence of gout and related uric acid levels in Sudbury, Massachusetts. In: Bennett PH, Wood PHN, editors. Population studies of the rheumatic diseases. Amsterdam: Excerpta Medica; 1968. p. 371–6.

98.

Cea Soriano L, Rothenbacher D, Choi HK, Garcia Rodriguez LA. Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther. 2011;R13:39. doi:10.1186/ar3272.

99.

Robinson P, Taylor W, Merriman T. A systematic review of the prevalence of gout and hyperuricemia in Australia. Intern Med J. 2012;42:997–1007. doi:10.1111/j.1445-5994.2012.02794.x.PubMed

100.

Torralba TP, Bayani Sioson PS. The Filipino and gout. Semin Arthritis Rheum. 1975;4:307–20.PubMed

101.

Hochberg MC, Thomas J, Thomas DJ, Mead L, Levine DM, Klag MJ. Racial differences in the incidence of gout. The role of hypertension. Arthritis Rheum. 1995;38:628–32.PubMed

102.

McAdams MA, Maynard JW, Baer AN, Kottgen A, Clipp S, Coresh J, et al. Reliability and sensitivity of the self-report of physician-diagnosed gout in the campaign against cancer and heart disease and the atherosclerosis risk in the community cohorts. J Rheumatol. 2011;38:135–41. doi:10.3899/jrheum.100418.PubMedCentralPubMed

Titel: Determinants of the prevalence of gout in the general population: a systematic review and meta-regression
verfasst von: José M. A. Wijnands
Wolfgang Viechtbauer
Kristof Thevissen
Ilja C. W. Arts
Pieter C. Dagnelie
Coen D. A. Stehouwer
Sjef van der Linden
Annelies Boonen
Publikationsdatum: 01.01.2015
Verlag: Springer Netherlands
Erschienen in: European Journal of Epidemiology / Ausgabe 1/2015
Print ISSN: 0393-2990
Elektronische ISSN: 1573-7284
DOI: https://doi.org/10.1007/s10654-014-9927-y

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Determinants of the prevalence of gout in the general population: a systematic review and meta-regression

Abstract

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

Should non-cardiovascular mortality be considered in the SCORE model? Findings from the Prevention of Renal and Vascular End-stage Disease (PREVEND) cohort

Fish consumption and mortality in the European Prospective Investigation into Cancer and Nutrition cohort

Overweight, obesity and risk of all-cause and cardiovascular mortality in patients with type 2 diabetes mellitus: a dose–response meta-analysis of prospective cohort studies

The European Journal of Epidemiology and the European Epidemiology Federation

Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population

Coffee consumption and risk of lung cancer: the ICARE study